Eugene III - Biofrontera Warrants Chief Officer
| BFRIW Stock | USD 0.13 0.05 64.77% |
Executive
Eugene III is Chief Officer of Biofrontera Warrants
| Age | 39 |
| Address | 120 Presidential Way, Woburn, MA, United States, 01801 |
| Phone | 781-245-1325 |
| Web | https://www.biofrontera-us.com |
Biofrontera Warrants Management Efficiency
The company has return on total asset (ROA) of (0.4024) % which means that it has lost $0.4024 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (1.4941) %, meaning that it generated substantial loss on money invested by shareholders. Biofrontera Warrants' management efficiency ratios could be used to measure how well Biofrontera Warrants manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.84 in 2024. Return On Capital Employed is likely to climb to -2.19 in 2024. At this time, Biofrontera Warrants' Total Assets are fairly stable compared to the past year. Non Current Assets Total is likely to climb to about 6.4 M in 2024, whereas Other Current Assets are likely to drop slightly above 4.7 M in 2024.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Charbel PharmD | Inhibrx | N/A | |
| Jeffrey Jensen | Inhibrx | N/A | |
| Renate Gloggner | Molecular Partners AG | 54 | |
| Daniel Steiner | Molecular Partners AG | N/A | |
| Ashraf Amanullah | Inhibrx | 56 | |
| David MBA | Inhibrx | N/A | |
| Brendan Eckelman | Inhibrx | 45 | |
| Bonne MBA | Inhibrx | 47 | |
| Dr Esq | Enliven Therapeutics | 47 | |
| MD MBA | Molecular Partners AG | N/A | |
| Pamela Trail | Molecular Partners AG | 68 | |
| Carlos Bais | Inhibrx | N/A | |
| Robert Hendriks | Molecular Partners AG | N/A | |
| Nishi MD | Eliem Therapeutics | N/A | |
| Anne DVM | Molecular Partners AG | N/A | |
| Zamaneh MD | Tff Pharmaceuticals | 60 | |
| MD MBA | Eliem Therapeutics | 50 | |
| Valerie Morisset | Eliem Therapeutics | 54 | |
| Helen MD | Enliven Therapeutics | 61 | |
| Emily Pimblett | Eliem Therapeutics | 40 | |
| Josep Garcia | Inhibrx | N/A | |
Management Performance
| Return On Equity | -1.49 | ||||
| Return On Asset | -0.4 |
Biofrontera Warrants Leadership Team
Elected by the shareholders, the Biofrontera Warrants' board of directors comprises two types of representatives: Biofrontera Warrants inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Biofrontera. The board's role is to monitor Biofrontera Warrants' management team and ensure that shareholders' interests are well served. Biofrontera Warrants' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Biofrontera Warrants' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Jon MBA, Vice Affairs | ||
| Daniel JD, General Compliance | ||
| Mark Baldyga, Vice Marketing | ||
| Alycia Torres, Vice Administration | ||
| Hermann Luebbert, President CEO | ||
| Samantha Widdicombe, Senior Communications | ||
| Eugene III, Chief Officer |
Biofrontera Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Biofrontera Warrants a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Biofrontera Stock Analysis
When running Biofrontera Warrants' price analysis, check to measure Biofrontera Warrants' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Biofrontera Warrants is operating at the current time. Most of Biofrontera Warrants' value examination focuses on studying past and present price action to predict the probability of Biofrontera Warrants' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Biofrontera Warrants' price. Additionally, you may evaluate how the addition of Biofrontera Warrants to your portfolios can decrease your overall portfolio volatility.